Myeloid Therapeutics Stock

Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.

Sign up today and learn more about Myeloid Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Myeloid Therapeutics Stock

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

Funding History

January 2021$50.0M
February 2023$96.0M
May 2023$73.0M


Chief Executive Officer & Co-Founder

Daniel Getts

Co-founder & Snr. Director, Discovery Research

Yuxiao Wang

Co-Founder & Chairman of Advisory Board

Siddhartha Mukherjee

Chief Business Officer

Darren Braccia


Ronald Vale

Chief Technology and Manufacturing Officer, Head of Technical Operations

Sadettin Ozturk


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: